Compound | Net residual cGMP | |
---|---|---|
2 min after Hb | 5 min after Hb | |
pmol/106 cells | ||
Glutamate (1 mM) | −0.21 ± 0.17 | |
Kainate (100 μM) | −0.58 ± 0.64 | |
(1S,3R)-ACPD (100 μM) | −0.57 ± 0.26 | |
Noradrenaline (100 μM) | 0.63 ± 0.57 | |
A23187 (10 μM) | 0.30 ± 0.80 | |
Nicardipine (300 μM) | 3.10 ± 0.23*** | |
EHNA (300 μM) | 1.44 ± 0.31* | |
Cilostamide (100 μM) | 1.01 ± 0.08*** | |
Sildenafil (300 μM) | 19.9 ± 0.34*** |
The cGMP level remaining in control cells (see Fig 1a) in each experiment has been subtracted (n = 3–6). The mean residual cGMP in control cells was 6.02 ± 1.33 pmol cGMP/106 cells (n = 6) after 2 min and 2.99 ± 0.26 pmol cGMP/106 cells (n = 8) after 5 min. Significance was determined by Student's unpairedt test (* P < 0.05; *** P < 0.001).